Aeterna Zentaris Continues to Demonstrate Pipeline Expansion ? Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
Aeterna Zentaris Inc Thu, March 11, 2021, 2:05 PM·9 min read
? Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism
? Continued execution on growth strategy to establish a diversified, yet focused, pipeline of development assets leveraging the Company?s expertise and experience
AEZS Earnings Date Earnings announcement* for AEZS: Mar 29, 2021
AEterna Zentaris Inc. is estimated to report earnings on 03/29/2021. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.05.